|
1
|
Khalil AB, Beshyah SA, Abdella N, Afandi B, Al-Arouj MM, Al-Awadi F, Benbarka M, Ben Nakhi A, Fiad TM, Al Futaisi A, Hassoun AA, Hussein W, Kaddaha G, Ksseiry I, Al Lamki M, Madani AA, Saber FA, Abdel Aal Z, Morcos B, Saadi H. Diabesity in the Arabian Gulf: Challenges and Opportunities. Oman Med J 2018; 33:273-282. [PMID: 30038726 DOI: 10.5001/omj.2018.53] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
Affiliation(s)
- Aly Bernard Khalil
- Department of Endocrinology, Imperial College London Diabetes Center, Abu Dhabi, UAE
| | - Salem A Beshyah
- Center for Diabetes and Endocrinology, Sheikh Khalifa Medical City, Abu Dhabi, UAE
| | - Nabila Abdella
- Department of Medicine, Faculty of Medicine, University of Kuwait City, Kuwait City, Kuwait
| | - Bachar Afandi
- Department of Endocrinology, Tawam Hospital, Al-Ain, UAE
| | | | | | | | | | - Tarek M Fiad
- Center for Diabetes and Endocrinology, Sheikh Khalifa Medical City, Abu Dhabi, UAE
| | - Abdullah Al Futaisi
- Department of Endocrinology, Sultan Qaboos University Hospital, Muscat, Oman
| | | | - Wiam Hussein
- Department of Endocrinology, Dr. Wiam Clinic for Diabetes and Endocrine Disorders, Riffa, Bahrain
| | - Ghaida Kaddaha
- Department of Diabetes and Endocrinology, Suliman Al Habib Hospital, Dubai Medical City, Dubai, UAE
| | - Iyad Ksseiry
- Department of Diabetes and Endocrinology, Mediclinic Hospital, Dubai, UAE
| | - Mohamed Al Lamki
- Department of Diabetes and Endocrinology, Royal Hospital, Muscat, Oman
| | | | - Feryal A Saber
- Department of Diabetes and Endocrinology, Bahrain Defense Force Hospital, Riffa, Bahrain
| | | | - Bassem Morcos
- Medical Affairs, Merck Sharp and Dohme Corp., Dubai, UAE
| | - Hussein Saadi
- Medical Subspecialties Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, UAE
| |
Collapse
|
|
2
|
Epler GR, Saber FA, Gaensler EA. Determination of severe impairment (disability) in interstitial lung disease. Am Rev Respir Dis 1980; 121:647-59. [PMID: 7386978 DOI: 10.1164/arrd.1980.121.4.647] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Physicians trained primarily to recognize and treat disease are being asked more frequently to quantify impairment of health. Criteria for defining impairment due to chronic obstructive pulmonary diseases are widely accepted, but it has been difficult to establish guidelines for interstitial diseases. To develop and validate criteria, we selected 2,420 patients with airflow obstruction; 821 had interstitial disease, and 938 were employees of asbestos industries. We found that clinical and roentgenographic criteria were inappropriate for defining impairment. The forced vital capacity and single-breath diffusing capacity, each expressed as a percentage of the predicted value, were selected for analysis. Sensitivity studies using response to standard exercise as an independent criterion suggested that the limits reflecting severe impairment were a forced vital capacity 50% of predicted and a single-breath diffusing capacity 40% of predicted. Applying these criteria, 35.6% of patients with interstitial pneumonia, 12.1% with sarcoidosis, and 13.6% with pneumoconioses, but only 1.1% of the workers exposed to asbestos were severely impaired. In more than one half of patients the single-breath diffusing capacity was the only test that indicated severe impairment.
Collapse
|